Thalassaemia Genetic Profile in Pakistan at Chughtai Lab

Thalassaemia Genetic Profile in Blood With History (Form NIBD) at Chughtai Lab

The Thalassaemia Genetic Profile in Blood With History (Form NIBD) at Chughtai Lab is a highly specialized molecular diagnostic test designed to identify genetic mutations responsible for thalassemia and other hemoglobinopathies. Thalassemia is an inherited blood disorder characterized by a reduction or complete absence of globin chain synthesis, leading to microcytic hypochromic anemia, ineffective erythropoiesis, and varying degrees of clinical severity. This comprehensive profile utilizes advanced DNA analysis techniques to evaluate the alpha-globin and beta-globin genes, providing a definitive diagnosis that standard hematological tests, such as a Complete Blood Count (CBC) or Hemoglobin Electrophoresis, cannot achieve alone. By integrating the patient's detailed clinical and family history through the National Institute of Blood Diseases (NIBD) referral form, this genetic profile ensures an exceptionally high level of diagnostic accuracy and clinical utility.

In Pakistan, where the carrier rate for beta-thalassemia is estimated to be between 5% and 8%, genetic profiling is a cornerstone of preventive hematology and family planning. The test works by extracting genomic DNA from a peripheral blood sample and analyzing it for specific mutations, deletions, or duplications in the HBA1, HBA2, and HBB genes. The inclusion of the NIBD history form is critical; it captures essential clinical parameters, including transfusion history, family pedigree, ethnic background, and previous hematological indices. This clinical correlation allows molecular pathologists at Chughtai Lab to interpret genetic variants of uncertain significance accurately, differentiate between silent carrier states and active disease, and provide actionable insights for genetic counseling, prenatal diagnosis, and personalized therapeutic management.

Clinical Procedure: What to Expect

Patient Preparation

Proper preparation is essential to ensure the integrity of the genetic sample and the accuracy of the clinical correlation. Patients undergoing the Thalassaemia Genetic Profile at Chughtai Lab should observe the following guidelines:

• No Fasting Required: Fasting is not necessary for this molecular test. Patients can eat and drink normally prior to sample collection.
• Complete the NIBD Form: The National Institute of Blood Diseases (NIBD) history form must be meticulously filled out by the referring physician or hematologist. This form must document the patient's age, gender, ethnic origin, family history of thalassemia, transfusion history (including the date of the last transfusion), and previous CBC and Hb Electrophoresis results.
• Document Recent Transfusions: If the patient has received a blood transfusion recently, this must be clearly noted on the history form. While blood transfusions do not alter the patient's own genomic DNA, they can temporarily affect hematological indices and circulating donor DNA ratios in highly sensitive assays.
• Bring Previous Records: Patients are advised to bring all previous medical records, particularly prior hematology reports, to the Chughtai Lab collection center to assist the diagnostic team.

During the Procedure

The collection of the blood sample for the genetic profile is a routine, safe, and quick procedure performed by trained phlebotomists at Chughtai Lab:

• Patient Identification and Verification: The phlebotomist will verify the patient's identity and confirm that the NIBD history form is fully completed and signed.
• Venipuncture Site Selection: The patient is seated comfortably, and a suitable vein, typically in the antecubital fossa of the arm, is selected. The area is thoroughly sanitized with an antiseptic swab.
• Sample Collection: A sterile, single-use needle is inserted into the vein to draw approximately 3 to 5 milliliters of venous blood. The blood is collected directly into an EDTA (purple-top) tube, which contains an anticoagulant that preserves cellular integrity and prevents DNA degradation.
• Post-Collection Care: The needle is gently removed, and a sterile cotton ball or adhesive bandage is applied to the puncture site. The patient is asked to apply light pressure for a few minutes to prevent bruising.
• Sample Transport and Processing: The collected sample, along with the NIBD history form, is labeled with a unique barcode and transported under controlled temperature conditions to the specialized molecular diagnostics division of Chughtai Lab for DNA extraction and analysis.

When is a Thalassaemia Genetic Profile Performed?

Pre-Marital Screening and Family Planning

The Thalassaemia Genetic Profile is frequently requested for couples planning to marry or conceive, particularly when there is a known family history of thalassemia or in regions with a high prevalence of the carrier state. If both partners are carriers of a beta-thalassemia mutation (thalassemia minor), there is a 25% chance with each pregnancy that their child will inherit both mutated genes and suffer from thalassemia major, a severe, transfusion-dependent life-threatening condition. Identifying carrier status through genetic profiling allows couples to make informed reproductive choices, seek genetic counseling, and explore options such as prenatal diagnosis or pre-implantation genetic testing.

Diagnostic Confirmation of Microcytic Hypochromic Anemia

Physicians order this genetic profile when a patient presents with persistent microcytic hypochromic anemia (characterized by low MCV and MCH levels) that does not respond to iron therapy, and where standard diagnostic tests yield inconclusive results. While iron deficiency anemia is common, it frequently coexists with or mimics thalassemia trait. Standard Hb Electrophoresis may occasionally miss silent alpha-thalassemia carriers or certain beta-thalassemia mutations with normal HbA2 levels. Molecular genetic testing provides the definitive, gold-standard confirmation needed to differentiate these conditions and prevent unnecessary, potentially harmful iron supplementation.

Prenatal Diagnosis in High-Risk Pregnancies

For pregnant couples who are confirmed carriers of thalassemia mutations, the Thalassaemia Genetic Profile is a critical tool for prenatal diagnosis. Chorionic villus sampling (CVS) or amniocentesis is performed to obtain fetal genetic material, which is then analyzed alongside the parents' genetic profiles. This allows clinical geneticists to determine whether the fetus has inherited normal genes, is a carrier, or is affected by thalassemia major. The clinical history and parental mutation data provided by the NIBD form are vital for targeting the specific mutations during fetal testing, ensuring rapid and highly accurate prenatal reporting.

Evaluation of Unexplained Severe Anemia in Infants

Infants presenting with progressive, severe anemia, failure to thrive, pallor, poor feeding, and hepatosplenomegaly within the first year of life are candidates for this test. These clinical signs are highly suggestive of beta-thalassemia major or intermedia. Because infant hemoglobin profiles are naturally transitioning from fetal hemoglobin (HbF) to adult hemoglobin (HbA) during this period, standard electrophoresis can sometimes be challenging to interpret. Genetic profiling directly identifies the causative mutations in the beta-globin gene, enabling early diagnosis, timely initiation of transfusion therapy, and appropriate clinical management.

Characterization of Complex Hemoglobinopathies and Silent Carriers

This genetic profile is indicated for patients suspected of carrying complex, rare, or silent hemoglobin variants. Some individuals inherit a combination of different hemoglobinopathies, such as sickle cell trait co-inherited with beta-thalassemia, or co-existing alpha and beta-thalassemia mutations. Furthermore, silent alpha-thalassemia carriers often exhibit completely normal hematological parameters and normal Hb Electrophoresis. Genetic profiling is the only diagnostic modality capable of mapping these intricate genetic interactions, providing a clear picture of the patient's genetic makeup and predicting the clinical phenotype of their offspring.

What Does a Thalassaemia Genetic Profile Detect?

The Thalassaemia Genetic Profile in Blood With History (Form NIBD) at Chughtai Lab is designed to detect a wide spectrum of genetic variations, mutations, and structural abnormalities within the globin gene clusters. Specifically, the profile evaluates and detects:

• Beta-Globin Gene (HBB) Point Mutations: Identifies common regional mutations such as IVS-1-5 (G-C), Fr 8-9 (+G), Fr 41-42 (-CTTT), Cap+1 (A-C), and IVS-1-1 (G-T).
• Beta-Thalassemia Major: Detects homozygous or compound heterozygous mutations in the HBB gene, indicating a complete or near-complete lack of beta-globin production.
• Beta-Thalassemia Intermedia: Identifies genetic profiles that result in moderate anemia, where patients may not require regular lifelong transfusions.
• Beta-Thalassemia Minor (Carrier Status): Detects heterozygous mutations in the HBB gene, characterizing healthy carriers who may exhibit mild microcytic anemia.
• Alpha-Globin Gene (HBA1/HBA2) Deletions: Identifies single or double gene deletions, such as the -alpha3.7 or -alpha4.2 single deletions, and –MED or –SEA double deletions.
• Silent Alpha-Thalassemia Carrier: Detects the loss of a single alpha-globin gene (-a/aa), which is clinically asymptomatic with normal hematological indices.
• Alpha-Thalassemia Trait: Identifies two-gene deletions in cis (–/aa) or trans (-a/-a), causing mild microcytic anemia.
• Hemoglobin H (HbH) Disease: Detects three-gene deletions (–/-a), leading to moderate-to-severe hemolytic anemia and splenomegaly.
• Alpha-Thalassemia Major (Hydrops Fetalis): Detects the deletion of all four alpha-globin genes (–/–), which is incompatible with life outside the womb.
• Hemoglobin S (HbS) Mutation: Detects the specific point mutation in the HBB gene responsible for Sickle Cell Anemia and Sickle Cell Trait.
• Hemoglobin E (HbE) Variant: Identifies the HbE mutation, common in certain ethnic groups, which can interact with beta-thalassemia to cause severe disease.
• Hemoglobin C (HbC) Variant: Detects the structural variant that can cause mild hemolytic anemia or interact with other hemoglobinopathies.
• Hemoglobin D-Punjab (HbD) Variant: Identifies this common structural variant, which is clinically benign in heterozygous form but significant when co-inherited with HbS or beta-thalassemia.
• Delta-Beta Thalassemia Deletions: Detects rare deletions that eliminate both delta and beta-globin gene expression, resulting in high levels of fetal hemoglobin (HbF).
• Hereditary Persistence of Fetal Hemoglobin (HPFH): Identifies genetic variations that cause continued high production of HbF into adulthood, which can ameliorate the severity of beta-thalassemia.
• Unstable Hemoglobin Variants: Detects rare mutations that cause hemoglobin molecules to precipitate within red blood cells, leading to hemolysis.
• Co-inheritance of Alpha and Beta Thalassemia: Identifies individuals who carry mutations in both alpha and beta-globin genes, which often results in a milder clinical presentation of beta-thalassemia.
• Triplicated Alpha-Globin Genes: Detects the presence of extra alpha-globin genes (aaa/), which can worsen the clinical severity of beta-thalassemia minor.
• Non-Deletional Alpha-Thalassemia Mutations: Identifies point mutations in the alpha-globin genes, such as Hb Constant Spring, which cause more severe clinical phenotypes than simple deletions.
• Genetic Modifiers of Thalassemia: Evaluates genetic loci that may influence the clinical severity of the disease, aiding in prognostic assessment.
• Rare and Novel Mutations: Utilizes sequencing technology to identify uncommon or newly documented mutations in the globin gene clusters.
• Correlation with Clinical History: Integrates genetic findings with the patient's transfusion history and clinical presentation documented on the NIBD form to deliver a comprehensive, clinically relevant diagnostic report.

Turnaround Time and Report Access at Chughtai Lab

Because the Thalassaemia Genetic Profile involves complex molecular techniques, including genomic DNA extraction, polymerase chain reaction (PCR) amplification, and DNA sequencing or multiplex ligation-dependent probe amplification (MLPA), the processing time is longer than standard blood tests. At Chughtai Lab, the turnaround time for this highly specialized profile is typically 10 to 14 working days. This timeframe ensures that rigorous quality control protocols are met and that the molecular findings are thoroughly correlated with the clinical history provided on the NIBD form.

Chughtai Lab offers multiple convenient methods for patients and referring physicians to access diagnostic reports. Once the report is finalized and verified by a consultant molecular pathologist, patients receive an SMS notification. Reports can be downloaded directly from the official Chughtai Lab website using the patient's case number and password. Additionally, reports are accessible via the Chughtai Lab Mobile App, available on both iOS and Android platforms, and can be sent directly to patients via WhatsApp. Physical copies of the reports can also be collected from any Chughtai Lab diagnostic center or home delivery can be arranged through their dedicated courier services.

Thalassaemia Genetic Profile Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Beta-Globin Gene (HBB) Analysis	Wild-type sequence (No mutations detected)	Heterozygous, homozygous, or compound heterozygous mutations (e.g., IVS-1-5, Fr 8-9)
Alpha-Globin Gene (HBA1/HBA2) Copy Number	Four functional alpha-globin genes (aa/aa)	One, two, three, or four gene deletions (e.g., -a/aa, -a/-a, –/-a, –/–)
Hemoglobin Variants (HbS, HbE, HbC, HbD)	Absent (Normal adult HbA composition)	Presence of structural variants in heterozygous or homozygous states
Delta-Beta Globin Gene Cluster	Intact gene structure	Deletions indicating Delta-Beta Thalassemia or HPFH
Alpha-Globin Gene Point Mutations	No mutations detected	Non-deletional mutations (e.g., Hb Constant Spring)
Clinical History & NIBD Form Correlation	Consistent with normal hematological profile	Discrepancies indicating recent transfusions, silent carrier status, or complex genetic interactions
Carrier Status Classification	Non-carrier	Confirmed Beta-Thalassemia Minor, Alpha-Thalassemia Trait, or Sickle Cell Trait

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient's symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Thalassaemia Genetic Profile?

• Expert Molecular Pathologists: Chughtai Lab employs highly qualified and experienced molecular pathologists and geneticists who specialize in interpreting complex hemoglobinopathy profiles.
• Advanced Molecular Technology: The laboratory utilizes state-of-the-art PCR, MLPA, and DNA sequencing platforms to ensure the highest analytical sensitivity and specificity.
• Comprehensive Clinical Correlation: By utilizing the specialized NIBD history form, Chughtai Lab ensures that genetic data is interpreted in the context of the patient's unique clinical and family history.
• Strict Quality Assurance: Chughtai Lab adheres to rigorous international quality control standards and participates in external quality assessment programs to guarantee accurate reporting.
• Extensive Network: With numerous collection centers across Pakistan, patients can easily submit samples and complete the required clinical documentation close to home.
• Convenient Digital Access: Patients can view, download, and share their genetic reports seamlessly through the Chughtai Lab mobile app, website, or WhatsApp.
• Home Sample Collection: Chughtai Lab offers professional home sample collection services, allowing patients to have their blood drawn in the comfort of their homes.
• Dedicated Genetic Counseling Support: The lab provides comprehensive reporting that serves as an invaluable tool for clinical geneticists and hematologists during post-test counseling.